Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06733935 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

A Phase 1 study of Systemic Sclerosis and Idiopathic Inflammatory Myopathies, sponsored by Nkarta.

Recruiting
Registry status
Phase 1
Development phase
144
Enrollment target
13
Study locations

NCT06733935 is a Phase 1 study of Systemic Sclerosis and Idiopathic Inflammatory Myopathies that is actively recruiting participants, run by Nkarta. The registered enrollment target is 144 participants, below the 274-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (47% lower). The trial reports 13 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06733935, a Phase 1 study of Systemic Sclerosis and Idiopathic Inflammatory Myopathies, is actively recruiting participants, sponsored by Nkarta.

RECRUITING
Registry status
Phase 1
Development phase
144 participants
Enrollment target
13
Study locations

Study Summary

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

Conditions Studied

Systemic Sclerosis Idiopathic Inflammatory Myopathies Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • DRUG NKX019

Study Locations (13)

Florida

  • Nkarta Investigational Site - Miami
  • Nkarta Investigational Site - Plantation

New York

  • Nkarta Investigational Site - Stony Brook
  • Nkarta Investigational Site - Syracuse

Texas

  • Nkarta Investigational Site - Dallas
  • Nkarta Investigational Site - Houston

California

  • Nkarta Investigational Site - Orange

Illinois

  • Nkarta Investigational Site - Chicago

Kansas

  • Nkarta Investigational Site - Fairway

Michigan

  • Nkarta Investigational Site - Ann Arbor

Minnesota

  • Nkarta Investigational Site - Minneapolis

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2024-11-04
Est. Completion 2028-10
Phase Phase 1

Sponsor

Nkarta

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06733935

The ClinicalTrials.gov registry entry for NCT06733935 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 274-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (47% lower). The listed sponsor is Nkarta, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Systemic Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT06733935 reports 13 study locations spanning 10 distinct geographic areas - top geographies include Florida, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT06733935 about?

NCT06733935 is a clinical study titled "A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)". This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

What is the current status of trial NCT06733935?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2024-11-04. Estimated completion is 2028-10.

What conditions does trial NCT06733935 study?

This clinical trial studies the following conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

What interventions are being tested in trial NCT06733935?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), NKX019 (DRUG).

Who is sponsoring clinical trial NCT06733935?

This trial is sponsored by Nkarta, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06733935 being conducted?

This trial has 13 study locations across California, Florida, Illinois, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Systemic Sclerosis

All registered trials for this condition

Idiopathic Inflammatory Myopathies

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.